Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol. 2017;18(6):719–31.

PubMed Central  Google Scholar 

Gajjar A, Bowers DC, Karajannis MA, Leary S, Witt H, Gottardo NG. Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol. 2015;33(27):2986–98.

CAS  PubMed Central  Google Scholar 

Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–47.

CAS  PubMed Central  Google Scholar 

Soppet D, Escandon E, Maragos J, Middlemas DS, Reid SW, Blair J, et al. The neurotrophic factors brain-derived neurotrophic factor and neurotrophin-3 are ligands for the trkB tyrosine kinase receptor. Cell. 1991;65(5):895–903.

CAS  Google Scholar 

Davies AM, Horton A, Burton LE, Schmelzer C, Vandlen R, Rosenthal A. Neurotrophin-4/5 is a mammalian-specific survival factor for distinct populations of sensory neurons. J Neurosci. 1993;13(11):4961–7.

CAS  PubMed Central  Google Scholar 

Nakagawara A, Liu XG, Ikegaki N, White PS, Yamashiro DJ, Nycum LM, et al. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics. 1995;25(2):538–46.

CAS  Google Scholar 

Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans Roy Soc Lond B Biol Sci. 2006;361(1473):1545–64.

CAS  Google Scholar 

Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.

CAS  PubMed Central  Google Scholar 

Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.

CAS  Google Scholar 

Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci. 2003;4(4):299–309.

CAS  Google Scholar 

Indo Y, Tsuruta M, Hayashida Y, Karim MA, Ohta K, Kawano T, et al. Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis. Nat Genet. 1996;13(4):485–8.

CAS  Google Scholar 

Greco A, Villa R, Fusetti L, Orlandi R, Pierotti MA. The Gly571Arg mutation, associated with the autonomic and sensory disorder congenital insensitivity to pain with anhidrosis, causes the inactivation of the NTRK1/nerve growth factor receptor. J Cell Physiol. 2000;182(1):127–33.

CAS  Google Scholar 

Yeo GS, Connie Hung CC, Rochford J, Keogh J, Gray J, Sivaramakrishnan S, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci. 2004;7(11):1187–9.

CAS  Google Scholar 

Xu B, Goulding EH, Zang K, Cepoi D, Cone RD, Jones KR, et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci. 2003;6(7):736–42.

CAS  PubMed Central  Google Scholar 

Smeyne RJ, Klein R, Schnapp A, Long LK, Bryant S, Lewin A, et al. Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. Nature. 1994;368(6468):246–9.

CAS  Google Scholar 

Klein R, Smeyne RJ, Wurst W, Long LK, Auerbach BA, Joyner AL, et al. Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell. 1993;75(1):113–22.

CAS  Google Scholar 

Barbacid M. The Trk family of neurotrophin receptors. J Neurobiol. 1994;25(11):1386–403.

CAS  Google Scholar 

Sun W, et al. Neuro-bone tissue engineering: emerging mechanisms, potential strategies, and current challenges. Bone Res. 2023;11(1):65.

CAS  PubMed Central  Google Scholar 

Su YW, Zhou XF, Foster BK, Grills BL, Xu J, Xian CJ. Roles of neurotrophins in skeletal tissue formation and healing. J Cell Physiol. 2018;233(3):2133–45.

CAS  Google Scholar 

Jin W, Yun C, Hobbie A, Martin MJ, Sorensen PH, Kim SJ. Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. Cancer Res. 2007;67(7):3192–200.

CAS  Google Scholar 

Ranzi V, Meakin SO, Miranda C, Mondellini P, Pierotti MA, Greco A. The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins. Endocrinology. 2003;144(3):922–8.

CAS  Google Scholar 

Westphalen CB, Krebs MG, Le Tourneau C, Sokol ES, Maund SL, Wilson TR, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021;5(1):69.

CAS  PubMed Central  Google Scholar 

Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46(5):444–50.

CAS  PubMed Central  Google Scholar 

Guerreiro Stucklin AS, Ryall S, Fukuoka K, Zapotocky M, Lassaletta A, Li C, et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun. 2019;10(1):4343.

PubMed Central  Google Scholar 

Chiang J, Bagchi A, Li X, Dhanda SK, Huang J, Pinto SN, et al, High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse—results from the SJYC07 trial and institutional experience. Neuro Oncol. 2023;26(1):178-190.

Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol. 2018;2018.

Zhao X, Kotch C, Fox E, Surrey LF, Wertheim GB, Baloch ZW, et al. NTRK fusions identified in pediatric tumors: the frequency, fusion partners, and clinical outcome. JCO Precis Oncol. 2021;1.

de la Cruz CC, Hunsaker T, Vazvaei F, Draganov D, Yu L, Merchant M. Determination of the efficacious entrectinib exposures required for pathway inhibition and anti-tumor activity in a subcutaneous and intracranial TPM3-NTRK1mutant tumor model. Cancer Res. 2019;79:3894.

Google Scholar 

Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, et al. Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor. J Med Chem. 2016;59(7):3392–408.

CAS  Google Scholar 

Fuse MJ, Okada K, Oh-Hara T, Ogura H, Fujita N, Katayama R. Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers. Mol Cancer Ther. 2017;16(10):2130–43.

CAS  Google Scholar 

US Food & Drug Administration. FDA approves larotrectinib for solid tumors with NTRK gene fusions. https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions. Accesed 23 July 2024.

US Food & Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf. Accesed 23 July 2024.

US Food & Drug Administration. FDA expands pediatric indication for entrectinib and approves new pellet formulation. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pediatric-indication-entrectinib-and-approves-new-pellet-formulation#:~:text=FDA%20expands%20pediatric%20indication%20for%20entrectinib%20and%20approves%20new%20pellet%20formulation,-Share&text=On%20October%2020%2C%202023%2C%20the,(Rozlytrek%2C%20Genentech%20Inc. Accesed 23 July 2024.

Hong DS, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21(4):531–40.

CAS  PubMed Central  Google Scholar 

Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018;19(5):705–14.

CAS  PubMed Central  Google Scholar 

Doz F, van Tilburg CM, Geoerger B, Højgaard M, Øra I, Boni V, et al. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022;24(6):997–1007.

CAS  Google Scholar 

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82.

CAS  Google Scholar 

Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, et al. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022;24(10):1776–89.

CAS  PubMed Central  Google Scholar 

Qin, H, Patel MR. The challenge and opportunity of NTRK inhibitors in non-small cell lung cancer. Int J Mol Sci. 2022;23(6):2916.

Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol. 2019;30(Suppl 8):viii23–30.

Murray BW, Rogers E, Zhai D, Deng W, Chen X, Sprengeler PA, et al. Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and resistant mutations. Mol Cancer Ther. 2021;20(12):2446–56.

CAS  PubMed Central  Google Scholar 

Laetsch TW, Hong DS. tropomyosin receptor kinase inhibitors for the treatment of TRK fusion cancer. Clin Cancer Res. 2021;27(18):4974–82.

CAS  Google Scholar 

Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016;6(1):36–44.

CAS  Google Scholar 

Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7(9):963–72.

CAS  PubMed Central  Google Scholar 

Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat Med. 2019;25(9):1422–7.

CAS  PubMed Central  Google Scholar 

Blauel ER, Laetsch TW. The promise of TRK inhibitors in pediatric cancers with NTRK fusions. Cancer Genet. 2022;262–263:71–9.

PubMed Central  Google Scholar 

Hemming ML, Nathenson MJ, Lin JR, Mei S, Du Z, Malik K, et al. Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. JCO Precis Oncol. 2020;4:79–90.

Google Scholar 

Chen MF, Yang SR, Shia J, Girshman J, Punn S, Wilhelm C, et al. Response to repotrectinib after development of NTRK resistance mutations on first- and second-generation TRK inhibitors. JCO Precis Oncol. 2023;7: e2200697.

PubMed Central